Tris Pharma Inc, a specialty pharmaceutical company, has signed a contract with Medison Pharma, an international commercial partner, it was reported on Tuesday.
The contract has been signed to give Medison Pharma exclusive rights to commercialise Tris Pharma's FDA-approved Quillivant treatment for Attention Deficit Hyperactivity Disorder (ADHD) in Israel.
Meir Jakobsohn, Medison founder and CEO, was quoted as saying: "We view ADHD as an area in which there is a significant unmet need in Israel, and we believe that Quillivant XR is uniquely well-positioned for the paediatric market. As the only FDA-approved long-acting methylphenidate suspension, Quillivant XR is a natural fit for children who have difficulty swallowing pills, and who can benefit from both the once-per-day dosing schedule and the customised dose and titration enabled by a liquid product."
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval